초록 ▼

The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention

The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.

대표청구항 ▼

1. A molecule comprising at least the antigen-binding portion of an antibody which has affinity for fibroblast growth factor receptor 2 (FGFR2), with cross-reactivity to fibroblast growth factor receptor 3 (FGFR3), which blocks both ligand-dependent and constitutive ligand-independent receptor activ

1. A molecule comprising at least the antigen-binding portion of an antibody which has affinity for fibroblast growth factor receptor 2 (FGFR2), with cross-reactivity to fibroblast growth factor receptor 3 (FGFR3), which blocks both ligand-dependent and constitutive ligand-independent receptor activation. 2. The molecule according to claim 1 wherein the antibody binds both FGFR2 and FGFR3 with affinity of at least 50 nM but is substantially devoid of affinity to fibroblast growth factor receptor 1 (FGFR1). 3. The molecule according to claim 1 wherein the antibody is selected from a monoclonal antibody having binding affinity to FGFR2 with cross-reactivity to FGFR3, a proteolytic fragment of said monoclonal antibody and a single chain antibody, wherein said fragment of an antibody is a single chain Fv having an amino acid sequence set forth in SEQ ID NO:5. 4. The molecule according to claim 3 wherein the antibody or antibody fragment is modified by PEGylation. 5. A pharmaceutical composition comprising at least one molecule comprising at least the antigen-binding portion of an antibody which has affinity for fibroblast growth factor receptor 2 (FGFR2) with cross-reactivity to fibroblast growth factor receptor 3 (FGFR3), which blocks both ligand-dependent and constitutive ligand-independent receptor activation; and a pharmaceutically acceptable carrier. 6. The pharmaceutical composition according to claim 5 wherein the molecule binds both FGFR2 and FGFR3 with affinity of at least 50 nM but is substantially devoid of affinity to fibroblast growth factor receptor 1 (FGFR1). 7. The pharmaceutical composition according to claim 5 wherein the molecule is selected from a monoclonal antibody having binding affinity to FGFR2 with cross-reactivity to FGFR3, a proteolytic fragment of said monoclonal antibody and a single chain antibody, wherein said fragment of an antibody is a single chain Fv having an amino acid sequence set forth in SEQ ID NO:5. 8. The pharmaceutical composition according to claim 7 wherein the antibody or antibody fragment is modified by PEGylation. 9. A molecule comprising at least the antigen-binding portion of an antibody which has affinity for fibroblast growth factor receptor 2 (FGFR2) with cross-reactivity to fibroblast growth factor receptor 3 (FGFR3), which blocks both ligand-dependent and constitutive ligand-independent receptor activation, wherein the antigen-binding portion comprises a single chain Fv having an amino acid sequence set forth in SEQ ID NO:5. 10. The molecule according to claim 9 wherein the antibody is modified by PEGylation. 11. A pharmaceutical composition comprising at least one molecule according to claim 9; and a pharmaceutically acceptable carrier. 12. A method for attenuating or treating bladder cancer associated with fibroblast growth factor receptor 2 (FGFR2), comprising administering to an individual in need thereof a therapeutically effective amount of the molecule according to claim 1; and a pharmaceutically acceptable carrier. 13. The method according to claim 12 wherein said molecule is selected from a monoclonal antibody, a proteolytic fragment of a monoclonal antibody and a single chain antibody, wherein said fragment of an antibody is a single chain Fv having an amino acid sequence set forth in SEQ ID NO:5. 14. The method according to claim 13 wherein said antibody or antibody fragment is modified by PEGylation. 15. A method for attenuating or treating bladder cancer associated with fibroblast growth factor receptor 2(FGFR2), comprising administering to an individual in need thereof a therapeutically effective amount of the molecule according to claim 9; and a pharmaceutically acceptable carrier. 16. A method for attenuating or treating bladder cancer associated with fibroblast growth factor receptor 2 (FGFR2), comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 11.